TDP43 autoregulation gives rise to shortened isoforms that are tightly controlled by both transcriptional and post-translational mechanisms

Megan M Dykstra,Kaitlin Weskamp,Nicolas B Gomez,Jacob Waksmacki,Elizabeth M Tank,M. Rebecca Glineburg,Allison Snyder,Emile Pinarbasi,Michael Bekier,Xingli Li,Jen Bai,Shameena Shahzad,Juno Nedumaran,Clare Wieland,Corey Stewart,Sydney Willey,Nikolas Grotewold,Jonathon McBride,John Moran,Aditya Suryakumar,Michael Lucas,Pete Tessier,Michael Ward,Peter Todd,Sami Barmada

DOI: https://doi.org/10.1101/2024.07.02.601776

2024-07-04

Abstract:The nuclear RNA-binding protein TDP43 is integrally involved in the pathogenesis of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). Previous studies uncovered N-terminal TDP43 isoforms that are predominantly cytosolic in localization, highly prone to aggregation, and enriched in susceptible spinal motor neurons. In healthy cells, however, these shortened (s)TDP43 isoforms are difficult to detect in comparison to full-length (fl)TDP43, raising questions regarding their origin and selective regulation. Here, we show that sTDP43 is created as a byproduct of TDP43 autoregulation and cleared by nonsense mediated RNA decay (NMD). The sTDP43-encoding transcripts that escape NMD can lead to toxicity but are rapidly degraded post-translationally. Circumventing these regulatory mechanisms by overexpressing sTDP43 results in neurodegeneration in vitro and in vivo via N-terminal oligomerization and impairment of flTDP43 splicing activity, in addition to RNA binding-dependent gain-of-function toxicity. Collectively, these studies highlight endogenous mechanisms that tightly regulate sTDP43 expression and provide insight into the consequences of aberrant sTDP43 accumulation in disease.

Neuroscience

What problem does this paper attempt to address?

The problem that this paper attempts to solve is about the mechanism of action of TDP43 protein in neurodegenerative diseases, especially how the short form (shortened, sTDP43) of TDP43 is regulated and its potential toxicity in diseases. Specifically, the research focuses on the following points: 1. **Mechanism of sTDP43 production**: The study found that sTDP43 is a by - product generated during the self - regulation process of TDP43, and these sTDP43 - encoded transcripts are mainly cleared through the nonsense - mediated mRNA decay (NMD) pathway. 2. **Stability of sTDP43**: The study confirmed through multiple experimental methods (such as qRT - PCR, immunoblotting, fluorescence microscopy, etc.) that the sTDP43 - encoded transcripts are unstable in cells and are easily degraded by NMD. At the same time, the sTDP43 protein itself also has high instability and is mainly rapidly degraded through the ubiquitin - proteasome system (UPS) and macroautophagy pathways. 3. **Toxicity mechanism of sTDP43**: The study further explored the toxic effects of sTDP43 accumulation on cells. The results showed that over - expression of sTDP43 can lead to neuronal death, and its toxicity mechanisms include N - terminal oligomerization, interference with the splicing activity of full - length TDP43 (flTDP43), and RNA - binding - dependent gain - of - function toxicity. 4. **Physiological and pathological regulation of sTDP43**: The study revealed that under normal conditions, the level of sTDP43 is strictly regulated, while in the disease state, abnormal accumulation of sTDP43 may lead to neurodegenerative diseases. In summary, this paper aims to deeply understand the regulatory mechanism of sTDP43 in healthy and disease states and its potential role in neurodegenerative diseases, providing new ideas and targets for the treatment of related diseases.

TDP43 autoregulation gives rise to shortened isoforms that are tightly controlled by both transcriptional and post-translational mechanisms

TDP-43 dysregulation of polyadenylation site selection is a defining feature of RNA misprocessing in ALS/FTD and related disorders

RNA-binding deficient TDP-43 drives cognitive decline in a mouse model of TDP-43 proteinopathy

TDP-43 loss induces extensive cryptic polyadenylation in ALS/FTD

A TDP-43 acetylation-mimic mutation that disrupts RNA-binding drives FTLD-like neurodegeneration in a mouse model of sporadic TDP-43 proteinopathy

Mis-spliced transcripts generate de novo proteins in TDP-43-related ALS/FTD

RNA/DNA Binding Protein TDP43 Regulates DNA Mismatch Repair Genes with Implications for Genome Stability

TDP-43 nuclear loss in FTD/ALS causes widespread alternative polyadenylation changes

Axonal TDP-43 condensates drive neuromuscular junction disruption through inhibition of local synthesis of nuclear encoded mitochondrial proteins

Molecular mechanisms linking loss of TDP-43 function to amyotrophic lateral sclerosis/frontotemporal dementia-related genes

Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43

Cytoplasmic TDP43 Binds microRNAs: New Disease Targets in Amyotrophic Lateral Sclerosis

TDP-43-M323K causes abnormal brain development and progressive cognitive and motor deficits associated with mislocalised and increased levels of TDP-43

TDP-43 represses cryptic exon inclusion in the FTD–ALS gene UNC13A

TDP-43 regulates LC3ylation in neural tissue through ATG4B cryptic splicing inhibition

Abnormal Splicing Events due to Loss of Nuclear Function of TDP-43: Pathophysiology and Perspectives

Targeting 14-3-3θ-mediated TDP-43 pathology in amyotrophic lateral sclerosis and frontotemporal dementia mice

TDP-43 Induces Mitochondrial Damage and Activates the Mitochondrial Unfolded Protein Response

Elevated nuclear TDP-43 induces constitutive exon skipping

TDP-43 pathology links innate and adaptive immunity in amyotrophic lateral sclerosis

TDP-43 pathology is sufficient to drive axon initial segment plasticity and hyperexcitability of spinal motoneurones in vivo in the TDP43-ΔNLS model of Amyotrophic Lateral Sclerosis